NDAORALTABLETPriority Review
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
INTELENCE (etravirine) by Johnson & Johnson is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2008.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTELENCE (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in 2008 for HIV-1 infection in antiretroviral treatment-experienced adults and children aged 2 years and older. It works by inhibiting HIV-1 reverse transcriptase, blocking viral replication in patients who have developed resistance to other antiretroviral drugs.
$0.005BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending ($5M) and declining claims; team likely focused on transition planning and managed care retention strategies.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
Started Oct 2020
54 enrolled
HIV Infections
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
Started Dec 2019
32 enrolled
Healthy
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir
Started Jan 2019
871 enrolled
HIV/AIDS
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
Started Jan 2015
170 enrolled
HIV-1 Infection
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
Started Feb 2014
42 enrolled
Infection, Human Immunodeficiency Virus
Worked on INTELENCE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.